Latest Breaking News On - கானக்கோர்ட் உண்மையானது அந்தோணி பெதிருக்ஸி - Page 1 : comparemela.com
Wednesday s analyst upgrades and downgrades - The Globe and Mail
theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Tuesday s analyst upgrades and downgrades - The Globe and Mail
theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Monday s analyst upgrades and downgrades - The Globe and Mail
theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Inside the Market’s roundup of some of today’s key analyst actions
Ahead of the start of first-quarter reporting season for Canadian banks next week, Canaccord Genuity analyst Scott Chan raised his earnings per share expectations by 3 per cent, citing “better credit conditions and continued tailwinds from market sensitive businesses.”
That led him to increase his target prices for shares of the Big 6 banks by an average of 3 per cent.
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Inside the Market’s roundup of some of today’s key analyst actions
Bausch Health Companies Inc. (BHC-N, BHC-T) is likely to “change dramatically” over the next 12-18 months, according to RBC Dominion Securities’ Douglas Miehm, who thinks the market is “only starting to understand the value that could be surfaced.”
After being “on the sidelines for more than five years,” the equity analyst now sees the path to the expected spin off its eye-care business and thinks the “implications of possible divestitures provide near-term upside potential.”